Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase 3 4Phase 1 4Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Non-Small-Cell Lung 58Breast Neoplasms 43Prostatic Neoplasms 32Lung Neoplasms 29Multiple Myeloma 23Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 17Ovarian Neoplasms 17Colorectal Neoplasms 17Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Carcinoma, Renal Cell 14Pancreatic Neoplasms 13Endometrial Neoplasms 12Small Cell Lung Carcinoma 11Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Myasthenia Gravis 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Burkitt Lymphoma 7Recurrence 6Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Adenocarcinoma 6Triple Negative Breast Neoplasms 5

Interventions

Oxaliplatin 2Irinotecan 2Fluorouracil 2Capecitabine 2zanidatamab 1niraparib 1neratinib 1ivosidenib 1futibatinib 1encorafenib 1durvalumab 1binimetinib 1Trastuzumab 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Biliary Tract Neoplasms × 30 days × Clear all
NCT03875235 2026-05-26

TOPAZ-1

AstraZeneca

Phase 3 Active not recruiting
810 enrolled 24 charts 1 FDA
Gastrointestinal

Biliary Tract Neoplasms

NCT07606599 2026-05-26

A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
398 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07582315 2026-05-22

A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
538 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡